Expert Insights

At the ASCO Annual Meeting, Luca Bertamini, MD, discusses the application of the newly established IMS/IMWG genomic risk classification in newly diagnosed multiple myeloma.

At the ASCO Annual Meeting, Mattia D'Agostino, MD, discusses long-term MRD analyses from the phase 2 FORTE trial.

Atish Choudhury, MD, PhD, discusses a case of oligometastatic hormone-sensitive prostate cancer, exploring the role of metastasis-directed therapy combined with intensified androgen deprivation.

Mark Garzotto, MD, discusses a novel intratumoral adenoviral therapy combined with radiotherapy for patients with intermediate- and high-risk prostate cancer.

Paul Oberstein, MD, discusses results from the OrigAMI-1 trial evaluating amivantamab monotherapy in chemorefractory RAS/BRAF wild-type metastatic colorectal cancer.

Cara Mathews, MD, discusses results from the cohort D2 of the phase 1/2 RAINFOL-01 study assessing rinatabart sesutecan plus bevacizumab in patients with recurrent ovarian cancer.

Ghassan Abou-Alfa, MD, discusses results from the phase 3 PROOF 301 trial evaluating infigratinib in patients with FGFR2 fusion-positive cholangiocarcinoma.

Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.

Alison Schram, MD, discusses results from the phase 2 eNRGy trial which led to the recent FDA approval of zenocutuzumab for patients with NRG1-fusion positive cholangiocarcinoma.

Rana McKay, MD, discusses results from the ARASEC trial evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.